Antibe Therapeutics To Raise $35.1 Million In Bought Deal

Money continues to be raised at a feverish pace in the capital markets, with Antibe Therapeutics (TSX: ATE) the latest firm to announce a significant bought deal financing. The company last night announced that it has entered into an arrangement with Canaccord Genuity to raise $35.1 million in a bought deal financing.

A total of 5.9 million units of the company are to be sold under the offering, with each unit priced at $6.00 each. Each unit contains one common share and one half of a common share purchase warrant, with each warrant containing an exercise price of $7.50 per share and an expiry three years from the date of issuance.

An over-allotment option has also been granted.

Net proceeds from the financing are to be used to fully fund phase three efficacy trials and the remaining non-clinical studies for its lead drug, as well as to complete IND-enabling studies for two products in its pipeline, as well as to advance new drug candidates. Finally, funds will also be used for working capital and general corporate purposes.

The financing is currently slated to close on February 24.

Antibe Therapeutics last traded at $7.00 on the TSX.


Information for this briefing was found via Sedar and Antibe Therapeutics. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Silver’s Finally Breaking the System | Keith Neumeyer – First Majestic

The Best News for Gold Was the Drop! – Peter Grandich

McEwen Copper: The Los Azules Feasibility Study

Recommended

Steadright To Conduct Multi-Phased Exploration At Historic Goundafa Polymetallic Mine

Goliath Resources Drills 10.72 g/t Gold Over 7.83 Metres At Surebet

Related News

Antibe Therapeutics Proposes Share Consolidation To Enable Potential Nasdaq Listing

It appears that Antibe Therapeutics (TSXV: ATE) is still mulling a share consolidation that it...

Wednesday, July 15, 2020, 10:04:38 PM

Antibe: Canaccord Cuts Price Target From $5.00 To $1.20 After Drug Pivot

In early August, Antibe Therapeutics Inc. (TSX: ATE) announced that they have paused their study...

Monday, October 18, 2021, 11:31:00 AM

Antibe Therapeutics Pauses Otenaproxesul Trial After Exceeding Safety Threshold

Antibe Therapeutics Inc. (TSX: ATE) shared today that it is putting on pause the absorption,...

Tuesday, August 3, 2021, 09:50:31 AM

Antibe Therapeutics: Canaccord Upgrades Price Target To $16.50

Earlier this week, Antibe Therapeutics (TSXV: ATE) announced a strategic licensing deal with Nuance Pharm...

Thursday, February 11, 2021, 04:07:00 PM

Canaccord Slashes Antibe Therapeutics Price Target A Month After Drug Trial Paused

On August 3, Antibe Therapeutics Inc. (TSX: ATE) announced that they have paused their study...

Wednesday, September 29, 2021, 11:44:00 AM